Based on the cash flow, Recce is running on fumes.
Basically relying on R&D advances for funds.
Unless the company:
• raises more cash
• is bought out
• enters into some form of arrangement with a large pharma
the end is near.
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
60.0¢ |
Change
0.020(3.45%) |
Mkt cap ! $122.3M | |||
| Open | High | Low | Value | Volume |
| 60.0¢ | 60.0¢ | 57.5¢ | $23.23K | 39.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3011 | 58.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 60.0¢ | 2101 | 1 |
View Market Depth
| Last trade - 16.10pm 24/05/2024 (20 minute delay) ? |
|
|||||
|
Last
58.5¢ |
Change
0.020 ( 0.86 %) |
||||
| Open | High | Low | Volume | ||
| 59.0¢ | 59.0¢ | 57.5¢ | 28189 | ||
| Last updated 14.20pm 24/05/2024 ? | |||||
| RCE (ASX) Chart |